Cosentyx’s performance in 2016

Launched in the US in 1Q15, Novartis’s (NVS) Cosentyx managed to report revenues of around $1,128 million in 2016. This performance gave the drug “blockbuster therapy” status. Cosentyx has reported robust sales worth around $400 million in 4Q16. However, Novartis expects modest growth in the drug’s sales in 1Q17 due to negotiations related to rebates that the company will have to pay to healthcare payers. However, the company is confident of robust sales for the drug in 2017 due to steadily increasing demand both in the US as well as in Europe. Cosentyx is currently competing with other psoriasis drugs such as Johnson & Johnson’s (JNJ) Stelara, AbbVie’s (ABBV) Humira, and Amgen’s (AMGN) Enbrel.

Novartis’s Cosentyx Managed to Achieve Blockbuster Status in 2016

Best-in-class drug

Cosentyx has demonstrated its superior clinical profile in terms of long-term efficacy in psoriasis (or PsO), psoriatic arthritis (or PsA), and ankylosing spondylitis (or AS) indications. The drug has also demonstrated its ability to inhibit disease progression for two years in PsA and AS indications. Plus, Consentyx has demonstrated a significant response from 94% of patients within 16 weeks of re-treatment with the drug.

Further, the drug has displayed a robust safety profile. There have been very few instances of injection site reactions with Cosentyx. Additionally, the drug has shown almost negligible immunogenicity, which implies that there’s hardly any immune response due to the drug. These characteristics have made Cosentyx a best-in-class Interleukin 17 (or IL-17) monoclonal antibody.

If Cosentyx manages to report solid revenue growth in 2017, it could have a positive impact on Novartis stock and on the Vanguard FTSE All-World ex-US ETF (VEU). Novartis makes up about 0.74% of VEU’s total portfolio holdings.

In the next article, we’ll discuss Cosentyx’s penetration across multiple indications.

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

14 Jun

Why Kimberly-Clark Stock May Stop Rising

WRITTEN BY Amit Singh

Kimberly-Clark (KMB) stock has risen 20.5% this year, boosted by the company’s better-than-expected sales and earnings during its last reported quarter. However, its stock could stop climbing. Here's why.

172.31.16.229